Article

Vaccines against botulism

Medical College of Wisconsin, Microbiology and Molecular Genetics BSB-256, Milwaukee, WI 53226, USA.
Current opinion in microbiology (Impact Factor: 7.22). 06/2012; 15(3):317-24. DOI: 10.1016/j.mib.2012.05.009
Source: PubMed

ABSTRACT The clostridial neurotoxins (CNTs) are the most toxic proteins for humans and include botulinum neurotoxins (BoNT) and tetanus neurotoxin (TeNT). CNT neurotropism is based upon the preferred binding and entry into neurons and specific cleavage of neuronal SNARE proteins. While chemically inactive TeNT toxoid remains an effect vaccine, the current pentavalent vaccine against botulism is in limited supply. Recent advances have facilitated the development of the next generation of BoNT vaccines, utilizing non-catalytic full-length BoNT or a subunit vaccine composed of the receptor binding domain of BoNT as immunogens. This review describes the issues and progress towards the production of a vaccine against botulism that will be effective against natural BoNT variants.

4 Followers
 · 
130 Views
  • Source
    Molecular Aspects of Medicine 02/1994; 15(2):79-193. DOI:10.1016/0098-2997(94)90043-4 · 10.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Tetanus and botulinum neurotoxins, produced by anaerobic bacteria of the genus Clostridium, are the most toxic proteins known and are the sole responsible for the pathogenesis of tetanus and botulism. They enter peripheral cholinergic nerve terminals and cleave proteins of the neuroexocytosis apparatus causing a persistent, but reversible, inhibition of neurotransmitter release. Botulinum neurotoxins are used in the therapy of many human syndromes caused by hyperactive cholinergic nerve terminals. Here we focus on the many advances that were recently made on the understanding of their molecular mechanism of action and on their use in human therapy.
    Acta Chimica Slovenica 12/2011; 58(4):702-707. · 0.81 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Arguably, vaccination represents the single most effective medical intervention ever developed. Yet, vaccines have failed to provide any or adequate protection against some of the most significant global diseases. The pathogens responsible for these vaccine-recalcitrant diseases have properties that allow them to evade immune surveillance and misdirect or eliminate the immune response. However, genomic and systems biology tools, novel adjuvants and delivery systems, and refined molecular insight into protective immunity have started to redefine the landscape, and results from recent efficacy trials of HIV and malaria vaccines have instilled hope that another golden age of vaccines may be on the horizon.
    Current Opinion in Biotechnology 03/2013; 24(6). DOI:10.1016/j.copbio.2013.02.015 · 8.04 Impact Factor